The Foundation for Sarcoidosis Research (FSR) has selected 13 clinical centers to participate in its new Clinical Data Registry, aimed at advancing the understanding and treatment of sarcoidosis. This initiative, announced on July 14, 2026, is supported by the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) and is expected to become a vital resource for researchers.
A New Era in Sarcoidosis Research
We are thrilled to partner with these 13 extraordinary institutions in launching the national FSR Clinical Data Registry,” said Mary McGowan, President and CEO of FSR.
- Brigham and Women’s Hospital
- Cedars-Sinai Medical Center
- Duke University
- Medical University of South Carolina
- Hospital for Special Surgery
- National Jewish Health
- NYU Grossman School of Medicine
- The Ohio State University
- Stanford University
- University of Minnesota
- University of Virginia
- UT Southwestern
- Yale University
This registry represents a significant step forward, as FSR has spent the past two years gathering insights from various stakeholders, including patients, caregivers, and healthcare professionals. Their feedback shaped the registry's data collection strategies.
The FSR Clinical Data Registry aims for geographic, ethnic, and environmental diversity, which is vital for creating a comprehensive data set that can improve patient diagnosis, care, and treatment outcomes. FSR's goal is to build a robust body of knowledge over the next 5-7 years that will lead to significant breakthroughs in sarcoidosis research.
The FSR Clinical Data Registry is a long-awaited opportunity to bring a large-scale multi-center study to this rare devastating disease,
Dr. Lisa Maier, Steering Committee Co-Chair, National Jewish Health
With the formal agreements set to be finalized soon, the implementation phase will begin, ensuring high-quality data collection. This registry will complement existing FSR initiatives, such as the FSR-SARC Patient Registry, which tracks patient-reported outcomes globally.
The establishment of the Clinical Data Registry is a landmark move for sarcoidosis research, reflecting a commitment to improving patient care through collaboration among top medical institutions.